Israeli start-up Ibex helps detect cancer using AI

Tackling cancer is one of the most significant public health challenges of the 21st century, and accurately detecting the presence of tumors is an essential part of this challenge.Tel Aviv-based Ibex Medical Analytics supports medical professionals through its AI-based technology, which is designed to be used in routine clinical practice.Ibex's Galen Prostate solution helps identify suspected cancer on prostate core-needle biopsies. It just received the CE-IVD Mark, the company announced last Thursday, marking the first time one of its products has received the certification of conformity to EU health, safety and protection standards.Ibex provides an important contribution in facing two challenges, the shortage of pathologists and the occurrence of human errors, CEO Joseph Mossel told The Jerusalem Post."When a person shows potential symptoms of cancer, the next step is a biopsy, an analysis of a sample of the affected tissues," he said. "The examination of the sample has to be carried out by a pathologist using a microscope. Pathology is a complex medical discipline that requires years of training, and the world is facing a shortage of these specialists, even in countries such as the US and the UK. There is a growing gap between supply and demand."Galen